BUZZ-Chimerix soars on plans to submit application for US FDA accelerated approval for its brain tumor drug

Reuters12-10

** Shares of biotech Chimerix CMRX.O rise 171.68% to $2.35 after the bell

** Company plans to submit an application seeking FDA's accelerated approval in the U.S. for its drug dordaviprone as a treatment for a type of glioma before year-end

** Adds it will be ready for a U.S. launch as early as Q3 2025

** CMRX is seeking approval of dordaviprone as a treatment for recurrent H3 K27M-mutant diffuse glioma, a type of tumor that forms in the brain

** Up to last close, stock down ~10% YTD

(Reporting by Sriparna Roy in Bengaluru)

((Sriparna.Roy@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2490089622?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-10 06:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2490089622","market":"us","top_or_hot":-1,"title":"BUZZ-Chimerix soars on plans to submit application for US FDA accelerated approval for its brain tumor drug","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Chimerix soars on plans to submit application for US FDA accelerated approval for its brain tumor drug</title></head><body><p>** Shares of biotech Chimerix <span>CMRX.O</span> rise 171.68% to $2.35 after the bell</p><p>** Company <span>plans</span> to submit an application seeking FDA's accelerated approval in the U.S. for its drug dordaviprone as a treatment for a type of glioma before year-end</p><p>** Adds it will be ready for a U.S. launch as early as Q3 2025</p><p>** CMRX is seeking approval of dordaviprone as a treatment for recurrent H3 K27M-mutant diffuse glioma, a type of tumor that forms in the brain</p><p>** Up to last close, stock down ~10% YTD</p><p> (Reporting by Sriparna Roy in Bengaluru)</p><p> ((Sriparna.Roy@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Chimerix soars on plans to submit application for US FDA accelerated approval for its brain tumor drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Chimerix soars on plans to submit application for US FDA accelerated approval for its brain tumor drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-10 06:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241209:nL4N3NA1M0:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BUZZ-Chimerix soars on plans to submit application for US FDA accelerated approval for its brain tumor drug** Shares of biotech Chimerix CMRX.O rise 171.68% to $2.35 after the bell** Company plans to ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241209:nL4N3NA1M0:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CMRX","symbol_name":"Chimerix Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241209:nL4N3NA1M0:1","article_id":"2490089622","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490089622","pubTimestamp":1733782207,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Chimerix soars on plans to submit application for US FDA accelerated approval for its brain tumor drug** Shares of biotech Chimerix CMRX.O rise 171.68% to $2.35 after the bell** Company plans to submit an application seeking FDA's accelerated approval in the U.S. for its drug dordaviprone as a treatment for a type of glioma before year-end** Adds it will be ready for a U.S. launch as early as Q3 2025** CMRX is seeking approval of dordaviprone as a treatment for recurrent H3 K27M-mutant diffuse glioma, a type of tumor that forms in the brain** Up to last close, stock down ~10% YTD  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CMRX":"Chimerix Inc.","BK4139":"生物科技","BK4583":"猴痘概念"},"translate_title":"BUZZ-Chimerix计划向美国FDA提交加速批准其脑瘤药物的申请，股价飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CMRX":0.9},"content_text":"BUZZ-Chimerix soars on plans to submit application for US FDA accelerated approval for its brain tumor drug** Shares of biotech Chimerix CMRX.O rise 171.68% to $2.35 after the bell** Company plans to submit an application seeking FDA's accelerated approval in the U.S. for its drug dordaviprone as a treatment for a type of glioma before year-end** Adds it will be ready for a U.S. launch as early as Q3 2025** CMRX is seeking approval of dordaviprone as a treatment for recurrent H3 K27M-mutant diffuse glioma, a type of tumor that forms in the brain** Up to last close, stock down ~10% YTD (Reporting by Sriparna Roy in Bengaluru) ((Sriparna.Roy@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490089622"}